SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
SGLT2HgB
Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.
1 other identifier
observational
80
1 country
1
Brief Summary
Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2022
CompletedStudy Start
First participant enrolled
June 3, 2022
CompletedFirst Posted
Study publicly available on registry
June 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2024
CompletedMay 14, 2024
May 1, 2024
1.5 years
June 2, 2022
May 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Hemoglobin
0-1-3 months
Erythropoetin
0-1-3 months
NT-proBNP
0-1-3 months
Interventions
Patients receive an SGLT2 inhibitor as part of theirn routine care.
Eligibility Criteria
Type 2 diabetic patients who visit the diabetes outpatient clinic in the University Hospital of Patras, Greece
You may qualify if:
- type 2 diabetes
- Hba1C\>7% on their current treatment
- introduction of SGLT2 inhibitor as part of their routine care
You may not qualify if:
- eGFR\<60 ml/min
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital of Patras
Pátrai, 26504, Greece
Biospecimen
Serum, urine
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 2, 2022
First Posted
June 7, 2022
Study Start
June 3, 2022
Primary Completion
December 1, 2023
Study Completion
June 1, 2024
Last Updated
May 14, 2024
Record last verified: 2024-05